Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Jan;39(1):238–240. doi: 10.1128/aac.39.1.238

In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens.

A L Barry 1, P C Fuchs 1
PMCID: PMC162515  PMID: 7695313

Abstract

Broth microdilution tests were carried out with 2,671 respiratory tract isolates from 19 medical centers throughout the continental United States. The tests compared a streptogramin (RP59500) to erythromycin, dirithromycin, clarithromycin, and azithromycin against Streptococcus pneumoniae, S. pyogenes, Haemophilus influenzae, and Moraxella catarrhalis. Against macrolide-susceptible strains, the potency of RP59500 was similar to that of the macrolides: the azalide, azithromycin, was two to four times more potent against H. influenzae. The azalide and three macrolides showed nearly complete cross-resistance. At 2.0 micrograms/ml or less, the streptogramin, RP59500, was active against both macrolide-resistant and -susceptible strains of S. pneumoniae (MIC for 50% of the strains tested, 0.25 microgram/ml; MIC for 90% of the strains tested, 0.5 microgram/ml).

Full Text

The Full Text of this article is available as a PDF (191.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Archer G. L., Auger P., Doern G. V., Ferraro M. J., Fuchs P. C., Jorgensen J. H., Low D. E., Murray P. R., Reller L. B., Stratton C. W. RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci. Diagn Microbiol Infect Dis. 1993 Mar-Apr;16(3):223–226. doi: 10.1016/0732-8893(93)90113-l. [DOI] [PubMed] [Google Scholar]
  2. Barry A. L., Pfaller M. A., Fuchs P. C. Haemophilus test medium versus Mueller-Hinton broth with lysed horse blood for antimicrobial susceptibility testing of four bacterial species. Eur J Clin Microbiol Infect Dis. 1993 Jul;12(7):548–553. doi: 10.1007/BF01970963. [DOI] [PubMed] [Google Scholar]
  3. Barry A. L., Pfaller M. A., Fuchs P. C., Packer R. R. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993. Antimicrob Agents Chemother. 1994 Oct;38(10):2419–2425. doi: 10.1128/aac.38.10.2419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fass R. J. In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci. Antimicrob Agents Chemother. 1991 Mar;35(3):553–559. doi: 10.1128/aac.35.3.553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fremaux A., Sissia G., Cohen R., Geslin P. In-vitro antibacterial activity of RP 59500, a semisynthetic streptogramin, against Streptococcus pneumoniae. J Antimicrob Chemother. 1992 Jul;30 (Suppl A):19–23. doi: 10.1093/jac/30.suppl_a.19. [DOI] [PubMed] [Google Scholar]
  6. Hardy D. J., Hensey D. M., Beyer J. M., Vojtko C., McDonald E. J., Fernandes P. B. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob Agents Chemother. 1988 Nov;32(11):1710–1719. doi: 10.1128/aac.32.11.1710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kirst H. A., Sides G. D. New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy. Antimicrob Agents Chemother. 1989 Sep;33(9):1419–1422. doi: 10.1128/aac.33.9.1419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Leclercq R., Nantas L., Soussy C. J., Duval J. Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics. J Antimicrob Chemother. 1992 Jul;30 (Suppl A):67–75. doi: 10.1093/jac/30.suppl_a.67. [DOI] [PubMed] [Google Scholar]
  9. Neu H. C., Chin N. X., Gu J. W. The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combination. J Antimicrob Chemother. 1992 Jul;30 (Suppl A):83–94. doi: 10.1093/jac/30.suppl_a.83. [DOI] [PubMed] [Google Scholar]
  10. Sanchez M. L., Flint K. K., Jones R. N. Occurrence of macrolide-lincosamide-streptogramin resistances among staphylococcal clinical isolates at a university medical center. Is false susceptibility to new macrolides and clindamycin a contemporary clinical and in vitro testing problem? Diagn Microbiol Infect Dis. 1993 Mar-Apr;16(3):205–213. doi: 10.1016/0732-8893(93)90111-j. [DOI] [PubMed] [Google Scholar]
  11. Washington J. A., 2nd, Wilson W. R. Erythromycin: a microbial and clinical perspective after 30 years of clinical use (1). Mayo Clin Proc. 1985 Mar;60(3):189–203. doi: 10.1016/s0025-6196(12)60219-5. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES